Hepatitis D News and Research

RSS

Hepatitis D is a viral infection that causes liver inflammation (swelling of the tissue which occurs due to injury or infection) and damage.

Positive results form INX-189 Phase 1b trial against hepatitis C virus

Inhibitex, today reported positive preliminary interim safety and antiviral data from the first two monotherapy cohorts of its ongoing Phase 1b clinical trial of INX-189, an oral NS5b nucleotide inhibitor being developed to treat chronic infections caused by hepatitis C virus.

10 Jan 2011

Ligand, Chiva Pharmaceuticals enter strategic relationship to develop multiple Ligand assets, technology

Ligand Pharmaceuticals Incorporated announced today that it has entered into a strategic relationship with Chiva Pharmaceuticals, to develop multiple Ligand assets and technology in China and potentially worldwide.

7 Jan 2011

Liver transplant recipients develop PTMS, face high risk of cardiovascular disease

Researchers from Israel have determined that more than half of liver transplant recipients develop post-transplantation metabolic syndrome, placing them at greater risk for cardiovascular disease.

7 Jan 2011

Scientists identify prognostic biomarker to treat patients with HCV

Scientists at Inserm and Institut Pasteur have performed biomarker discovery on patients being treated for chronic hepatitis C infection. Their work, published in The Journal of Clinical Investigation, demonstrates that the plasma levels of the protein IP-10 predict, prior to treatment initiation, the efficacy of treatment with pegylated-interferon and ribavirin.

6 Jan 2011

Dongsheng obtains exclusive sales rights of Thymosin Alpha 1 Injection in China

Dongsheng Pharmaceutical International Co., Ltd. announced today that it has obtained the exclusive sales rights of Thymosin Alpha 1 Injection in 19 provinces in China from Shanghai Biochemistry Pharmaceutical Co. I.

5 Jan 2011

Anadys begins ANA598 Phase IIb study for hepatitis C

Anadys Pharmaceuticals, Inc. announced today that it has initiated the planned Phase IIb study of ANA598 in combination with pegylated interferon and ribavirin. The protocol for the study has been cleared by the United States Food and Drug Administration and Health Canada.

4 Jan 2011

Hepatitis A scare at Long Island church

Health officials have warned that parishioners who received Holy Communion during Christmas Mass at a church on Long Island may have been exposed to hepatitis A and may need vaccinated as soon as possible. Particularly those who received Communion at the 10.30am and 12pm (local time) masses on December 25, 2010, at Our Lady of Lourdes Church in Massapequa Park should get the shots.

4 Jan 2011

Immunitor reports positive safety imm01 clinical trial against tuberculosis

Immune Network Ltd., advises that Immunitor has published data from the first half of the 120-patient imm01 clinical trial of its V5 immunomodulator product against tuberculosis, including difficult-to-treat forms of the disease.

30 Dec 2010

Molecular interaction between structural HCV protein and protein critical to viral replication identified

Scientists from the Florida campus of The Scripps Research Institute have identified a molecular interaction between a structural hepatitis C virus protein (HCV) and a protein critical to viral replication. This new finding strongly suggests a novel method of inhibiting the production of the virus and a potential new therapeutic target for hepatitis C drug development.

29 Dec 2010

Vertex announces modification of telaprevir and VX-222 combination Phase 2 trial for treatment of HCV

Vertex Pharmaceuticals Incorporated today announced a modification of its Phase 2 clinical trial evaluating 12-week, response-guided regimens of its lead investigational hepatitis C virus (HCV) protease inhibitor, telaprevir, in combination with its lead investigational HCV polymerase inhibitor, VX-222.

22 Dec 2010

Pro-Pharmaceuticals, Mount Sinai collaborate to evaluate anti-fibrotic effects of Galectin-targeting compounds

Pro-Pharmaceuticals, Inc., the leading developer of Galectin therapeutics to treat cancer and fibrosis, today announced it has entered into a new research collaboration with Mount Sinai School of Medicine to evaluate in pre-clinical models, the anti-fibrotic effects of several of the Company's novel, Galectin-targeting compounds.

21 Dec 2010

Idera reports positive data from IMO-2125/ribavirin combination Phase 1 trial in null-responder HCV patients

Idera Pharmaceuticals, Inc. announced today preliminary data from a 4-week dose-ranging Phase 1 clinical trial of IMO-2125 in combination with ribavirin in 60 treatment-naïve patients with genotype 1 chronic hepatitis C virus (HCV) infection. In the trial, treatment with IMO-2125 in combination with ribavirin was well tolerated and achieved substantial decline in virus levels at two days after the first dose of IMO-2125 and after four weeks of treatment.

20 Dec 2010

Gene variant linked to liver cirrhosis in Caucasians

A new study by German researchers found that a variation in the PNPLA3 (adiponutrin) gene was associated with cirrhosis of the liver and elevated transaminase (liver enzyme) levels in alcoholic Caucasians. The risk of cirrhosis in alcoholics in the genetic high risk group might be as high as 25 to 50%. Full findings are published in the January 2011 issue of Hepatology, a journal of the American Association for the Study of Liver Diseases.

16 Dec 2010

Gene variation linked to liver cirrhosis in alcoholic caucasians

16 Dec 2010

AmoyDx receives SFDA approval for its EGFR and BRAF mutations detection kits

Amoy Diagnostics announced today that its EGFR and BRAF mutation detection kits received market approval from China's State Food and Drug Administration (SFDA). The SFDA is the competent authority for regulating drugs and in vitro diagnostics in mainland China. The approval allows AmoyDx to market the EGFR and BRAF tests for clinical use in China.

15 Dec 2010

Researchers introduce new class of drugs for HCV patients

To improve the care for individuals infected with the hepatitis C virus, a major health problem and a leading cause of chronic liver disease around the world, nearly 200 international hepatitis experts have taken an important step in escalating the introduction of a new class of targeted therapies for HCV – direct-acting antivirals.

15 Dec 2010

Y-90 microspheres pack a therapeutic punch against late-stage liver cancer

The latest weapon against inoperable liver cancer is so tiny that it takes millions of them per treatment, but according to interventional radiologists at the Indiana University School of Medicine, those microscopic spheres really pack a therapeutic punch.

15 Dec 2010

Pharmasset initiates dosing in PSI-7977 exploratory study in HCV

Pharmasset, Inc. announced today that dosing has begun in an exploratory study of PSI-7977, a nucleotide analog polymerase inhibitor, for the treatment of chronic hepatitis C (HCV). The trial will evaluate PSI-7977 400mg QD in combination with ribavirin (RBV), with 0, 4, 8, or 12 weeks of pegylated interferon alfa 2a (Peg-IFN) in treatment-naive patients infected with HCV genotype 2 or 3.

14 Dec 2010

Biostar provides update on preliminary sales for October and November 2010

Biostar Pharmaceuticals, Inc., Xianyang-based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsules, and a variety of pharmaceutical products, today provided an update on preliminary sales for October and November 2010.

13 Dec 2010

Digestive Disease Specialists deploys Wolters Kluwer Health's ProVation MD software

Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that Digestive Disease Specialists, Inc. has selected its ProVation MD software for gastroenterology procedure documentation and coding.

9 Dec 2010

Hepatitis D News and Research

Further Reading

Positive results form INX-189 Phase 1b trial against hepatitis C virus

Ligand, Chiva Pharmaceuticals enter strategic relationship to develop multiple Ligand assets, technology

Liver transplant recipients develop PTMS, face high risk of cardiovascular disease

Scientists identify prognostic biomarker to treat patients with HCV

Dongsheng obtains exclusive sales rights of Thymosin Alpha 1 Injection in China

Anadys begins ANA598 Phase IIb study for hepatitis C

Hepatitis A scare at Long Island church

Immunitor reports positive safety imm01 clinical trial against tuberculosis

Molecular interaction between structural HCV protein and protein critical to viral replication identified

Vertex announces modification of telaprevir and VX-222 combination Phase 2 trial for treatment of HCV

Pro-Pharmaceuticals, Mount Sinai collaborate to evaluate anti-fibrotic effects of Galectin-targeting compounds

Idera reports positive data from IMO-2125/ribavirin combination Phase 1 trial in null-responder HCV patients

Gene variant linked to liver cirrhosis in Caucasians

Gene variation linked to liver cirrhosis in alcoholic caucasians

AmoyDx receives SFDA approval for its EGFR and BRAF mutations detection kits

Researchers introduce new class of drugs for HCV patients

Y-90 microspheres pack a therapeutic punch against late-stage liver cancer

Pharmasset initiates dosing in PSI-7977 exploratory study in HCV

Biostar provides update on preliminary sales for October and November 2010

Digestive Disease Specialists deploys Wolters Kluwer Health's ProVation MD software

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News